Last €18.75 EUR
Change Today +0.10 / 0.54%
Volume 37.2K
GS7 On Other Exchanges
New York
As of 1:33 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GS7) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/20/14 - €20.86
52 Week Low
08/8/14 - €17.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GLAXOSMITHKLINE PLC (GS7)

glaxosmithkline plc (GS7) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc (GS7) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc (GS7) Key Developments

GlaxoSmithKline plc Receives FDA Approval for Arnuity(TM) Ellipta(R)

GlaxoSmithKline plc announced that the FDA has approved Arnuity(TM) Ellipta(R) (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. The approved doses are Arnuity Ellipta 100mcg and 200mcg. Arnuity Ellipta is administered once daily via the dry powder inhaler called Ellipta, which is also used across a range of other approved respiratory medicines in the GSK portfolio.

Pernix Therapeutics Holdings, Inc., GlaxoSmithKline plc - M&A Call

To discuss the acquisition of Treximet

Investors Reportedly Selected For Bidding For MGlaxoSmithKline's Portfolio Of Mature Drugs

Mylan, Inc. (NasdaqGS:MYL), TPG Capital LLP, Advent International Corporation, Kohlberg Kravis Roberts & Co. L.P. (NYSE:KKR) and Warburg Pincus LLC have made it through to the second round of bidding for a portfolio of mature drugs being sold by GlaxoSmithKline plc (LSE:GSK) in a transaction valued at approximately £2 billion, Wall Street Journal reported citing people familiar with the sales process. The sales process is expected to resume in early September 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GS7:GR €18.75 EUR +0.10

GS7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $139.38 USD +0.69
AstraZeneca PLC 4,567 GBp +87.50
Bayer AG €102.36 EUR +1.59
Novo Nordisk A/S kr259.00 DKK +1.00
PepsiCo Inc $92.49 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation GS7 Industry Range
Price/Earnings 14.8x
Price/Sales 2.8x
Price/Book 11.2x
Price/Cash Flow 14.6x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at